Home

Two recent studies shed light on how HMGB1 contributes to Kaposi’s sarcoma (KS) and small cell lung cancer (SCLC), revealing new potential therapeutic strategies for cancer.

In 2025 HMGBiotech Srl proudly marks its 20th anniversary, a milestone that reflects two decades of dedication to advancing research on HMGB1 protein.

A recent study highlights how higher HMGB1 levels correlate with liver fibrosis progression in individuals with HIV-HBV co-infection, despite suppressive antiretroviral therapy (ART).

Elevated HMGB1 levels are strongly associated with epilepsy severity and drug resistance, making it a valuable biomarker for clinical research. A recent study has demonstrated the potential of HMGB1-targeted interventions.

A recent research has highlighted how HMGB1 (High Mobility Group Box 1) protein in its reduced form plays a crucial role in enhancing cancer cell migration and invasiveness through its interaction with the chemokine CXCL12.

The role of High Mobility Group Box Protein 1 (HMGB1) is increasingly emerging in diabetes-associated complications, particularly diabetic encephalopathy (DE) and diabetic kidney disease (DKD).

High-Mobility Group Box-1 protein (HMGB1) plays a core role in the link between ulcerative colitis (UC) and colorectal cancer (CRC), particularly in colitic carcinoma.

Targeting HMGB1 could represent a novel therapeutic approach for mental health disorders related to stroke and sepsis.

World Mental Health Day, occurring on the 10th of October, recalls to us the importance of researches linking inflammation and mental health disorders, in particular major depressive disorder (MDD).